3 Vaccine Stocks to Buy as the FDA Cracks Down on New Variants

On Friday, the U.S. Federal Drug Administration (FDA) okayed the launch of updated vaccines as part of the 2024-2025 campaign against new Covid strains. Drug manufacturers have been waiting on approval from the agency, whose decision-making was complicated by the fact that the virus keeps mutating. FDA settled on targeting JN.1 — the variant responsible for most Covid cases of early this year. A vaccine targeting JN. 1 should offer broader protection against its offshoots KP.2, KP.3 and others that may pop ...